HighTower Advisors LLC Sells 1,575 Shares of Harrow, Inc. (NASDAQ:HROW)

HighTower Advisors LLC reduced its stake in Harrow, Inc. (NASDAQ:HROW) by 15.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,900 shares of the company’s stock after selling 1,575 shares during the quarter. HighTower Advisors LLC’s holdings in Harrow were worth $399,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of HROW. Quest Partners LLC purchased a new position in shares of Harrow in the 3rd quarter worth about $29,000. nVerses Capital LLC bought a new stake in Harrow in the second quarter worth about $33,000. Allspring Global Investments Holdings LLC boosted its stake in Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after acquiring an additional 2,048 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after acquiring an additional 227 shares during the period. Finally, Hills Bank & Trust Co purchased a new stake in shares of Harrow during the 3rd quarter worth approximately $107,000. 72.76% of the stock is currently owned by institutional investors.

Harrow Trading Down 0.6 %

Shares of HROW opened at $34.22 on Monday. Harrow, Inc. has a twelve month low of $9.13 and a twelve month high of $59.23. The stock has a market cap of $1.22 billion, a PE ratio of -36.40 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business’s 50-day moving average price is $44.55 and its 200-day moving average price is $36.78.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HROW. Craig Hallum increased their price objective on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 4th. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, October 4th. Finally, B. Riley lowered their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.